HK1126758A1 - Cyclopenta [d] pyrimidines as akt protein kinase inhibitors - Google Patents

Cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Info

Publication number: HK1126758A1
Authority: HK; Hong Kong
Prior art keywords: cyclopenta; pyrimidines; protein kinase; kinase inhibitors; akt protein
Prior art date: 2006-07-06

Application number

HK09105437.1A

Other languages

English (en)

Inventor

Ian S Mitchell

James F Blake

Rui Xu

Nicholas C Kallan

Dengming Xiao

Keith Lee Spencer

Josef R Bencsik

Jun Liang

Brian Safina

Jun Li

Christine Chabot

Anna L Banka

Eli M Wallace

Stephen T Schlachter

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-06

Filing date

2009-06-17

Publication date

2009-09-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1126758(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-06-17 Application filed by Genentech Inc filed Critical Genentech Inc

2009-09-11 Publication of HK1126758A1 publication Critical patent/HK1126758A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Neurology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
Dermatology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)

HK09105437.1A 2006-07-06 2009-06-17 Cyclopenta [d] pyrimidines as akt protein kinase inhibitors HK1126758A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US81876206P	2006-07-06	2006-07-06
PCT/US2007/072876 WO2008006032A1 (en)	2006-07-06	2007-07-05	Cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Publications (1)

Publication Number	Publication Date
HK1126758A1 true HK1126758A1 (en)	2009-09-11

Family

ID=38686844

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK09105437.1A HK1126758A1 (en)	2006-07-06	2009-06-17	Cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Country Status (32)

Country	Link
US (3)	US8003651B2 (xx)
EP (1)	EP2049500B1 (xx)
JP (3)	JP5268904B2 (xx)
KR (2)	KR101527232B1 (xx)
CN (2)	CN101631778B (xx)
AR (1)	AR061844A1 (xx)
AT (1)	ATE523499T1 (xx)
AU (1)	AU2007269052B2 (xx)
BR (1)	BRPI0713555A2 (xx)
CA (1)	CA2656618C (xx)
CL (1)	CL2007001992A1 (xx)
CO (1)	CO6160229A2 (xx)
CR (2)	CR10601A (xx)
CY (1)	CY1112142T1 (xx)
DK (1)	DK2049500T3 (xx)
ES (1)	ES2372955T3 (xx)
HK (1)	HK1126758A1 (xx)
HR (1)	HRP20110882T1 (xx)
IL (1)	IL196051A (xx)
MA (1)	MA30952B1 (xx)
MX (1)	MX2008016203A (xx)
MY (1)	MY147628A (xx)
NO (1)	NO20090580L (xx)
NZ (1)	NZ573979A (xx)
PL (1)	PL2049500T3 (xx)
PT (1)	PT2049500E (xx)
RS (1)	RS52210B (xx)
RU (1)	RU2481336C2 (xx)
SI (1)	SI2049500T1 (xx)
TW (1)	TWI428335B (xx)
UA (1)	UA99597C2 (xx)
WO (1)	WO2008006032A1 (xx)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8063050B2 (en)	2006-07-06	2011-11-22	Array Biopharma Inc.	Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
RS52210B (en)	2006-07-06	2012-10-31	Array Biopharma, Inc.	CYCLOPENT [D] PYRIMIDINS AS PROTEIN KINASE ACTION INHIBITORS
CN101516891B (zh) *	2006-07-06	2013-06-05	阵列生物制药公司	作为akt蛋白激酶抑制剂的二氢噻吩并嘧啶
AU2014201211B2 (en) *	2006-07-06	2016-04-14	Array Biopharma Inc.	Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
DE602007011628D1 (de) *	2006-07-06	2011-02-10	Array Biopharma Inc	Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
UA95641C2 (xx) *	2006-07-06	2011-08-25	Эррей Биофарма Инк.	Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US9409886B2 (en)	2007-07-05	2016-08-09	Array Biopharma Inc.	Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
KR20150091196A (ko)	2007-07-05	2015-08-07	어레이 바이오파마 인크.	Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US8846683B2 (en)	2007-07-05	2014-09-30	Array Biopharma, Inc.	Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
BRPI0813999A2 (pt)	2007-07-05	2019-10-01	Array Biopharma Inc	ciclopentanos de pirimidil como inibidores de akt proteína cinase
ES2394759T3 (es)	2008-01-08	2013-02-05	Array Biopharma, Inc.	Pirrolopiridinas como inhibidores de quinasa
CN101965347B (zh)	2008-01-09	2013-01-02	阵列生物制药公司	作为激酶抑制剂的吡唑并吡啶
US8324221B2 (en)	2008-01-09	2012-12-04	Array Biopharma Inc.	Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US8329709B2 (en)	2008-01-09	2012-12-11	Genentech, Inc.	5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors
CN101932565B (zh) *	2008-01-09	2013-06-12	阵列生物制药公司	作为akt蛋白激酶抑制剂的羟基化嘧啶基环戊烷
CN101932564B (zh)	2008-01-09	2012-12-26	阵列生物制药公司	作为akt蛋白激酶抑制剂的羟基化嘧啶基环戊烷类
US20100048914A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP3023433A1 (en)	2009-02-05	2016-05-25	Tokai Pharmaceuticals, Inc.	Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US20100233733A1 (en) *	2009-02-10	2010-09-16	Nodality, Inc., A Delaware Corporation	Multiple mechanisms for modulation of the pi3 kinase pathway
CN103038643A (zh) *	2010-04-16	2013-04-10	基因泰克公司	作为pi3k/akt激酶途径抑制剂效能的预测性生物标记的foxo3a
PT2694072T (pt)	2011-04-01	2018-02-26	Genentech Inc	Combinação de composto inibidor de akt e abiraterona para utilização em tratamentos terapêuticos
MX2013011333A (es)	2011-04-01	2014-04-16	Genentech Inc	Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.
US9266895B2 (en)	2012-09-10	2016-02-23	Principia Biopharma Inc.	Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
KR20150127720A (ko)	2013-03-14	2015-11-17	유니버시티 오브 매릴랜드, 발티모어	안드로겐 수용체 하향 조절제 및 그의 용도
CA2938626A1 (en)	2013-07-26	2015-01-29	John Rothman	Compositions to improve the therapeutic benefit of bisantrene
CA2920317A1 (en)	2013-08-12	2015-02-19	Tokai Pharmaceuticals, Inc.	Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
MY174153A (en) *	2013-11-15	2020-03-11	Hoffmann La Roche	Processes for the preparation of pyrimidinylcyclopentane compounds
US10092569B2 (en)	2014-02-21	2018-10-09	Principia Biopharma Inc.	Salts and solid form of a BTK inhibitor
JP2017530948A (ja) *	2014-08-27	2017-10-19	ペプティメド，インコーポレイテッド	抗腫瘍組成物および方法
CN107257686B (zh)	2014-12-18	2021-01-29	普林斯匹亚生物制药公司	天疱疮的治疗
MA42242A (fr)	2015-06-24	2018-05-02	Principia Biopharma Inc	Inhibiteurs de la tyrosine kinase
US10722484B2 (en)	2016-03-09	2020-07-28	K-Gen, Inc.	Methods of cancer treatment
CN115054586B (zh)	2016-06-29	2024-08-02	普林斯匹亚生物制药公司	改性的释放制剂
EP3762381A4 (en) *	2018-03-06	2022-01-05	Icahn School of Medicine at Mount Sinai	SERINE THREONINE KINASE (AKT) DEGRADATION / INTERRUPTION COMPOUNDS AND METHODS OF USE
TWI830733B (zh) *	2018-05-11	2024-02-01	中國大陸商迪哲（江蘇）醫藥有限公司	環戊烷化合物
IT201800005561A1 (it) *	2018-05-21	2019-11-21		Metodo per la pulizia dei denti mediante una composizione in polvere a base di idrossiapatite.
CN112996518A (zh)	2018-06-21	2021-06-18	西奈山伊坎医学院	Wd40重复结构域蛋白5(wdr5)降解/破坏化合物和使用方法
US20220144821A1 (en)	2019-01-29	2022-05-12	Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.	Akt inhibitor
WO2021118924A2 (en)	2019-12-12	2021-06-17	Ting Therapeutics Llc	Compositions and methods for the prevention and treatment of hearing loss
CN115485276B (zh) *	2020-05-15	2024-05-31	南京正大天晴制药有限公司	氘代akt激酶抑制剂
US12103924B2 (en)	2020-06-01	2024-10-01	Icahn School Of Medicine At Mount Sinai	Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
EP4186902A4 (en)	2020-07-22	2024-06-05	Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.	DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE SALT, PREPARATION METHOD AND USE THEREOF
JP7562828B2 (ja) *	2020-07-22	2024-10-07	南京正大天晴制薬有限公司	Ａｋｔ阻害剤の単位剤形組成物
WO2023109540A1 (zh) *	2021-12-17	2023-06-22	中国医药研究开发中心有限公司	具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3885035A (en) *	1972-04-05	1975-05-20	Sandoz Ag	Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
US3956495A (en) *	1973-10-30	1976-05-11	Eli Lilly And Company	2,4-Diaminoquinazolines as antithrombotic agents
US3966936A (en) *	1974-02-21	1976-06-29	Pfizer Inc.	Piperazino quinazoline bronchodilators
US4060615A (en) *	1976-02-18	1977-11-29	Mead Johnson & Company	2-Piperazinyl-6,7-dimethoxyquinazolines
US4051412A (en) *	1976-09-02	1977-09-27	General Electric Company	Discharge lamp operating circuit
JPS562968A (en) *	1979-06-21	1981-01-13	Mitsubishi Yuka Yakuhin Kk	Novel pyrimidine derivative
US4749704A (en)	1985-03-07	1988-06-07	Sankyo Company Limited	Cyclopenta[d]pyrimidine derivatives and use as antidepressants
EP0799617A3 (en)	1986-02-24	1997-11-12	Mitsui Petrochemical Industries, Ltd.	Therapeutic agent for neurological diseases
US4871739A (en)	1987-01-21	1989-10-03	Merck & Co., Inc.	Substituted 6H-7,8-dihydrothiapyrano(3,2-D)-pyrimidines as hyopglycemic agents
US4889856A (en)	1987-08-31	1989-12-26	Merck & Co., Inc.	7,8-dihydro-4-(1-pierazinyl)-6H-thiopyrano-[3,2-d] pyrimidines as β-blockers
US4994464A (en)	1987-08-31	1991-02-19	Merck & Co., Inc.	Piperazinylpyrimidines as β-adrenergic receptor blockers
MX19185A (es)	1989-01-20	1993-12-01	Pfizer	Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas.
JP2932693B2 (ja) *	1992-10-05	1999-08-09	宇部興産株式会社	ピリミジン化合物
EP0710654A4 (en) *	1993-07-23	1996-08-28	Green Cross Corp	TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE
GB9416189D0 (en) *	1994-08-10	1994-09-28	Merck Sharp & Dohme	Therapeutic agents
US5750531A (en) *	1994-08-13	1998-05-12	Yuhan Corporation	Pyrimidine derivatives and processes for the preparation thereof
US5525625A (en) *	1995-01-24	1996-06-11	Warner-Lambert Company	2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US7125880B1 (en) *	1995-06-06	2006-10-24	Pfizer Inc.	Corticotropin releasing factor antagonists
ZA979961B (en) *	1996-11-15	1999-05-05	Lilly Co Eli	5-HT1F agonists
UA73073C2 (uk)	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6310060B1 (en) *	1998-06-24	2001-10-30	Warner-Lambert Company	2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
JP2002509536A (ja)	1997-07-01	2002-03-26	ワーナー−ランバート・カンパニー	２−（４−ブロモ又は４−ヨードフェニルアミノ）安息香酸誘導体及びｍｅｋ阻害物質としてのそれらの使用
US6821963B2 (en) *	1997-07-01	2004-11-23	Warner-Lambert Company	4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6506798B1 (en) *	1997-07-01	2003-01-14	Warner-Lambert Company	4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
BR9810366A (pt)	1997-07-01	2000-08-29	Warner Lambert Co	Derivados de ácido 4-bromo ou 4-iodo fenilamino benzidroxîmico e seu uso como inibidores de mek
CA2326324C (en) *	1998-03-31	2010-05-11	Kyowa Hakko Kogyo Co., Ltd.	Nitrogen-containing heterocyclic compound
DE19853278A1 (de) *	1998-11-19	2000-05-25	Aventis Pharma Gmbh	Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CA2350234A1 (en)	1999-01-07	2000-07-13	Alexander James Bridges	Treatment of asthma with mek inhibitors
JP2002534381A (ja)	1999-01-07	2002-10-15	ワーナー−ランバート・カンパニー	Ｍｅｋ阻害剤を用いた抗ウィルス法
ES2251851T3 (es)	1999-01-13	2006-05-01	Warner-Lambert Company Llc	Acidos sulfohidroxamicos y sulfohidroxamatos y su uso com inhibidores mek.
AU2483400A (en)	1999-01-13	2000-08-01	Warner-Lambert Company	4'heteroaryl diarylamines
CA2355470C (en)	1999-01-13	2008-09-30	Warner-Lambert Company	Benzoheterocycles and their use as mek inhibitors
EP1144371B1 (en)	1999-01-13	2005-11-09	Warner-Lambert Company Llc	Benzenesulphonamide derivatives and their use as mek inhibitors
CN1149204C (zh) *	1999-01-13	2004-05-12	沃尼尔·朗伯公司	1-杂环取代的二芳基胺
CA2348236A1 (en)	1999-01-13	2000-07-20	Stephen Douglas Barrett	4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
GB9910577D0 (en)	1999-05-08	1999-07-07	Zeneca Ltd	Chemical compounds
TR200200205T2 (tr)	1999-07-16	2002-06-21	Warner-Lambert Company	MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
AU6068600A (en)	1999-07-16	2001-02-05	Warner-Lambert Company	Method for treating chronic pain using mek inhibitors
PL352705A1 (en)	1999-07-16	2003-09-08	Warner-Lambert Company	Method for treating chronic pain using mek inhibitors
KR20020012315A (ko)	1999-07-16	2002-02-15	로즈 암스트롱, 크리스틴 에이. 트러트웨인	Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
GB0003636D0 (en) *	2000-02-16	2000-04-05	Smithkline Beecham Plc	Novel compounds
AU2001247372A1 (en)	2000-03-15	2001-09-24	Warner Lambert Company	5-amide substituted diarylamines as mex inhibitors
GEP20053496B (en)	2000-07-19	2005-04-25	Warner Lambert Co	Oxygenated Esters of 4-Iodo Phenylamino Benzhydroxamic Acids
EP1313694A1 (en)	2000-08-25	2003-05-28	Warner-Lambert Company	Process for making n-aryl-anthranilic acids and their derivatives
KR20030030005A (ko)	2000-09-15	2003-04-16	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제 억제제로서 유용한 피라졸 화합물
JP2004514718A (ja)	2000-11-02	2004-05-20	アストラゼネカ　アクチボラグ	抗癌剤としての置換キノリン類
WO2002083139A1 (en)	2001-04-10	2002-10-24	Merck & Co., Inc.	Inhibitors of akt activity
RU2003134646A (ru) *	2001-04-30	2005-04-20	Глэксо Груп Лимитед (GB)	Конденсированные пиримидины в качестве антагонистов кортикотропинвысокобождающего фактора (crf)
BR0209267A (pt) *	2001-04-30	2004-06-15	Glaxo Group Ltd	Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf)
US7115741B2 (en) *	2001-09-06	2006-10-03	Levy Daniel E	4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
WO2003049678A2 (en)	2001-12-06	2003-06-19	Merck & Co., Inc.	Mitotic kinesin inhibitors
US20030187026A1 (en) *	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
JP4469179B2 (ja) *	2002-01-23	2010-05-26	バイエルファーマセチカルコーポレーション	Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
TW200306819A (en)	2002-01-25	2003-12-01	Vertex Pharma	Indazole compounds useful as protein kinase inhibitors
DE60330227D1 (de) *	2002-03-13	2010-01-07	Array Biopharma Inc	N3-alkylierte benzimidazol-derivate als mek-hemmer
DOP2003000614A (es)	2002-03-13	2009-09-30	Array Biopharma Inc	Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole
US7235537B2 (en) *	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
CA2481241C (en)	2002-04-08	2010-07-27	Merck & Co., Inc.	Fused quinoxaline derivatives as inhibitors of akt activity
JP4394959B2 (ja)	2002-04-08	2010-01-06	メルクエンドカムパニーインコーポレーテッド	Ａｋｔ活性の阻害剤
EP1496906A4 (en)	2002-04-08	2006-05-03	Merck & Co Inc	INHIBITORS OF AKT ACTIVITY
WO2003086394A1 (en)	2002-04-08	2003-10-23	Merck & Co., Inc.	Inhibitors of akt activity
EP1503761A1 (en)	2002-05-10	2005-02-09	Neurocrine Biosciences, Inc.	Substituted piperazines as melanocortin receptor ligands
US20040102360A1 (en) *	2002-10-30	2004-05-27	Barnett Stanley F.	Combination therapy
WO2004041162A2 (en)	2002-10-30	2004-05-21	Merck & Co., Inc.	Inhibitors of akt activity
EA200500721A1 (ru)	2002-11-28	2005-12-29	Шеринг Акциенгезельшафт	Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
GB0308208D0 (en) *	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds
CN1809351A (zh)	2003-04-24	2006-07-26	麦克公司	Akt活性抑制剂
US6994380B2 (en) *	2003-06-02	2006-02-07	Cooke Jr Charles M	High pressure quick connect coupling and seal
DE602004022819D1 (de) *	2003-06-06	2009-10-08	Vertex Pharma	Von atp-bindende kassette transportern
PE20050355A1 (es)	2003-08-05	2005-05-16	Vertex Pharma	Composiciones referidas a inhibidores de canales ionicos regulados por voltaje
CN100398524C (zh) *	2003-08-12	2008-07-02	弗·哈夫曼-拉罗切有限公司	作为crf拮抗剂的四氢喹唑啉衍生物
JPWO2005026126A1 (ja) *	2003-09-09	2006-11-16	小野薬品工業株式会社	Ｃｒｆ拮抗剤および二環式複素環化合物
WO2005039564A1 (en) *	2003-10-02	2005-05-06	Vertex Pharmaceuticals Incorporated	Phthalimide compounds useful as protein kinase inhibitors
EP1684694A2 (en) *	2003-11-21	2006-08-02	Array Biopharma, Inc.	Akt protein kinase inhibitors
EP1750727A2 (en)	2004-04-23	2007-02-14	Exelixis, Inc.	Kinase modulators and methods of use
MXPA06014747A (es)	2004-06-28	2007-02-16	Altana Pharma Ag	Pirimidinas 4,6-disustituidas y su uso como inhibidores de proteina cinasa.
US20060025074A1 (en) *	2004-07-30	2006-02-02	Chih-Ming Liang	Bluetooth-based headset
TWM266655U (en) *	2004-09-23	2005-06-01	Blueexpert Technology Corp	Bluetooth earphone device capable of wirelessly receiving and transmitting stereo sound signal and digital information signal
TW200621257A (en)	2004-10-20	2006-07-01	Astellas Pharma Inc	Pyrimidine derivative fused with nonaromatic ring
UY29177A1 (es)	2004-10-25	2006-05-31	Astex Therapeutics Ltd	Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
ATE543821T1 (de) *	2004-12-28	2012-02-15	Exelixis Inc	Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen
US20090111805A1 (en)	2005-02-24	2009-04-30	Pfizer Inc.	Bicyclic heteroaromatic derivatives useful as anticancer agents
WO2006127587A1 (en) *	2005-05-20	2006-11-30	Vertex Pharmaceuticals Incorporated	Pyrrolopyridines useful as inhibitors of protein kinase
AR054485A1 (es)	2005-06-21	2007-06-27	Cancer Rec Tech Ltd	ARIL-ALQUILAMINAS Y HETEROARIL-ALQUILAMINAS COMO INHIBIDORES DE PROTEINA QUINASA A Y B, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ORIGINADAS EN EL CRECIMIENTO ANORMAL DE LA
WO2007042298A1 (en)	2005-10-13	2007-04-19	Glaxo Group Limited	Pyrrolopyrimidine derivatives as syk inhibitors
AR056893A1 (es)	2005-12-28	2007-10-31	Takeda Pharmaceutical	Compuestos heterociclicos fusionados y no fusionados, antagonistas de receptores mineralocorticoides
US20090124610A1 (en)	2006-04-25	2009-05-14	Gordon Saxty	Pharmaceutical compounds
KR20090024834A (ko)	2006-07-05	2009-03-09	인터뮨, 인크.	Ｃ형 간염 바이러스 복제의 신규 억제제
GB0613518D0 (en)	2006-07-06	2006-08-16	Phytopharm Plc	Chemical compounds
US7910747B2 (en)	2006-07-06	2011-03-22	Bristol-Myers Squibb Company	Phosphonate and phosphinate pyrazolylamide glucokinase activators
UA95641C2 (xx)	2006-07-06	2011-08-25	Эррей Биофарма Инк.	Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
DK2049478T3 (da)	2006-07-06	2012-07-09	Glaxo Group Ltd	Substituerede N-phenylmethyl-5-oxoprolin-2-amider som P2X7-receptorantagonister og fremgangsmåder til anvendelse deraf
TW200808325A (en)	2006-07-06	2008-02-16	Astrazeneca Ab	Novel compounds
RS52210B (en)	2006-07-06	2012-10-31	Array Biopharma, Inc.	CYCLOPENT [D] PYRIMIDINS AS PROTEIN KINASE ACTION INHIBITORS
WO2008012635A2 (en)	2006-07-26	2008-01-31	Pfizer Products Inc.	Amine derivatives useful as anticancer agents

2007
- 2007-07-05 RS RS20110519A patent/RS52210B/en unknown
- 2007-07-05 AU AU2007269052A patent/AU2007269052B2/en not_active Expired - Fee Related
- 2007-07-05 BR BRPI0713555-6A patent/BRPI0713555A2/pt not_active Application Discontinuation
- 2007-07-05 AT AT07799329T patent/ATE523499T1/de active
- 2007-07-05 US US11/773,946 patent/US8003651B2/en not_active Expired - Fee Related
- 2007-07-05 CN CN2007800330546A patent/CN101631778B/zh not_active Expired - Fee Related
- 2007-07-05 MY MYPI20090025A patent/MY147628A/en unknown
- 2007-07-05 CA CA2656618A patent/CA2656618C/en not_active Expired - Fee Related
- 2007-07-05 NZ NZ573979A patent/NZ573979A/en not_active IP Right Cessation
- 2007-07-05 WO PCT/US2007/072876 patent/WO2008006032A1/en active Application Filing
- 2007-07-05 MX MX2008016203A patent/MX2008016203A/es active IP Right Grant
- 2007-07-05 UA UAA200900828A patent/UA99597C2/ru unknown
- 2007-07-05 SI SI200730779T patent/SI2049500T1/sl unknown
- 2007-07-05 DK DK07799329.3T patent/DK2049500T3/da active
- 2007-07-05 PT PT07799329T patent/PT2049500E/pt unknown
- 2007-07-05 JP JP2009518634A patent/JP5268904B2/ja not_active Expired - Fee Related
- 2007-07-05 ES ES07799329T patent/ES2372955T3/es active Active
- 2007-07-05 CN CN2013101365018A patent/CN103288753A/zh active Pending
- 2007-07-05 EP EP07799329A patent/EP2049500B1/en active Active
- 2007-07-05 KR KR1020097002436A patent/KR101527232B1/ko not_active IP Right Cessation
- 2007-07-05 KR KR1020157007785A patent/KR20150041164A/ko not_active Application Discontinuation
- 2007-07-05 RU RU2009103899/04A patent/RU2481336C2/ru not_active IP Right Cessation
- 2007-07-05 PL PL07799329T patent/PL2049500T3/pl unknown
- 2007-07-06 CL CL200701992A patent/CL2007001992A1/es unknown
- 2007-07-06 AR ARP070103035A patent/AR061844A1/es unknown
- 2007-07-06 TW TW096124776A patent/TWI428335B/zh not_active IP Right Cessation
2008
- 2008-12-18 IL IL196051A patent/IL196051A/en not_active IP Right Cessation
2009
- 2009-02-03 MA MA31611A patent/MA30952B1/fr unknown
- 2009-02-04 CO CO09010511A patent/CO6160229A2/es unknown
- 2009-02-05 CR CR10601A patent/CR10601A/es unknown
- 2009-02-05 NO NO20090580A patent/NO20090580L/no not_active Application Discontinuation
- 2009-06-17 HK HK09105437.1A patent/HK1126758A1/xx not_active IP Right Cessation
2011
- 2011-06-14 US US13/160,351 patent/US8846681B2/en not_active Expired - Fee Related
- 2011-11-28 HR HR20110882T patent/HRP20110882T1/hr unknown
- 2011-12-05 CY CY20111101202T patent/CY1112142T1/el unknown
2013
- 2013-05-07 JP JP2013097595A patent/JP5586735B2/ja not_active Expired - Fee Related
- 2013-06-05 JP JP2013118690A patent/JP2013231040A/ja not_active Withdrawn
2014
- 2014-05-09 CR CR20140215A patent/CR20140215A/es unknown
- 2014-08-11 US US14/456,670 patent/US20140349996A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20110245230A1 (en)	2011-10-06
MA30952B1 (fr)	2009-12-01
SI2049500T1 (sl)	2012-01-31
TW200817372A (en)	2008-04-16
CN101631778A (zh)	2010-01-20
IL196051A0 (en)	2009-09-01
CN101631778B (zh)	2013-05-08
JP5268904B2 (ja)	2013-08-21
RU2009103899A (ru)	2010-08-20
JP2009542721A (ja)	2009-12-03
NO20090580L (no)	2009-04-06
CR20140215A (es)	2014-07-11
MX2008016203A (es)	2009-01-27
CA2656618C (en)	2014-08-26
KR20090029287A (ko)	2009-03-20
CL2007001992A1 (es)	2008-07-18
JP5586735B2 (ja)	2014-09-10
DK2049500T3 (da)	2011-12-12
AU2007269052B2 (en)	2014-10-23
BRPI0713555A2 (pt)	2012-03-20
RU2481336C2 (ru)	2013-05-10
EP2049500A1 (en)	2009-04-22
US20140349996A1 (en)	2014-11-27
JP2013231040A (ja)	2013-11-14
US8003651B2 (en)	2011-08-23
CO6160229A2 (es)	2010-05-20
AR061844A1 (es)	2008-09-24
KR101527232B1 (ko)	2015-06-09
CY1112142T1 (el)	2015-11-04
EP2049500B1 (en)	2011-09-07
TWI428335B (zh)	2014-03-01
PL2049500T3 (pl)	2012-02-29
RS52210B (en)	2012-10-31
CA2656618A1 (en)	2008-01-10
KR20150041164A (ko)	2015-04-15
ATE523499T1 (de)	2011-09-15
HRP20110882T1 (hr)	2012-01-31
IL196051A (en)	2012-10-31
CR10601A (es)	2009-02-20
NZ573979A (en)	2012-02-24
ES2372955T3 (es)	2012-01-30
PT2049500E (pt)	2011-12-23
AU2007269052A1 (en)	2008-01-10
WO2008006032A1 (en)	2008-01-10
MY147628A (en)	2012-12-31
JP2013209381A (ja)	2013-10-10
CN103288753A (zh)	2013-09-11
US20080058327A1 (en)	2008-03-06
UA99597C2 (xx)	2012-09-10
US8846681B2 (en)	2014-09-30

Publication	Publication Date	Title
HK1126758A1 (en)	2009-09-11	Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
HK1160134A1 (en)	2012-08-10	Hydroxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors akt [d]
HK1150605A1 (en)	2012-01-06	5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
EP2497470B8 (en)	2015-12-02	Imidazotriazines and imidazopyrimidines as kinase inhibitors
IL195238A0 (en)	2009-08-03	Pyrazolo [1,5-a]pyrimidines as cdk inhibitors
HK1146042A1 (en)	2011-05-13	Pyrimidine derivatives as protein kinase inhibitors
ZA200806313B (en)	2009-12-30	Pyrrolo [3,2-c]pyridine-4-one 2-indolinone protein kinase inhibitors
IL204721A0 (en)	2010-11-30	Pyrrolo [2,3 - d] pyrimidin derivatives as protein kinase b inhibitors
HK1158947A1 (en)	2012-07-27	Macrocyclic pyrimidines as protein kinase inhibitors
HK1147255A1 (en)	2011-08-05	Pyrimidyl cyclopentanes as akt protein kinase inhibitors
IL197231A0 (en)	2009-12-24	Pyrimidines derivatives and their use as kinase inhibitors
IL195005A0 (en)	2009-08-03	Inhibitors of akt (protein kinase b)
IL199378A0 (en)	2010-03-28	2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors
IL194491A0 (en)	2009-08-03	Thiazolyldihydroindazole derivatives as protein kinase inhibitors
ZA200810573B (en)	2009-09-30	Substituted 3-cyanopyridines as protein kinase inhibitors
ZA200809545B (en)	2010-01-27	Inhibitors of Akt (protein kinase B)

Legal Events

Date	Code	Title	Description
2021-02-19	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20200705